IL7R

Summary

IL7R (interleukin 7 receptor, HGNC:6024) is a protein-coding gene on chromosome 5p13.2, encoding Interleukin-7 receptor subunit alpha (P16871). Receptor for interleukin-7.

The protein encoded by this gene is a receptor for interleukin 7 (IL7). The function of this receptor requires the interleukin 2 receptor, gamma chain (IL2RG), which is a common gamma chain shared by the receptors of various cytokines, including interleukins 2, 4, 7, 9, and 15. This protein has been shown to play a critical role in V(D)J recombination during lymphocyte development. Defects in this gene may be associated with severe combined immunodeficiency (SCID). Alternatively spliced transcript variants have been found.

Source: NCBI Gene 3575 — RefSeq curated summary.

At a glance

• Gene–disease (curated): immunodeficiency 104 (Definitive, ClinGen) — +2 more curated relationships
• GWAS associations: 43
• Clinical variants (ClinVar): 605 total — 46 pathogenic, 15 likely-pathogenic
• Phenotypes (HPO): 59
• Cancer driver (intOGen): activating (oncogene-like) across 4 cancer types
• MANE Select transcript: NM_002185

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:6024
Approved symbol	IL7R
Name	interleukin 7 receptor
Location	5p13.2
Locus type	gene with protein product
Status	Approved
Aliases	CD127, IL7RA, lnc-IL7R, IL-7Ralpha, IL7Ralpha, sIL-7R, CDw127
Ensembl gene	ENSG00000168685
Ensembl biotype	protein_coding
OMIM	146661
Entrez	3575

Gene structure

Transcript identifiers

Ensembl transcripts: 11 — 7 protein_coding, 2 retained_intron, 1 protein_coding_CDS_not_defined, 1 nonsense_mediated_decay

ENST00000303115, ENST00000505093, ENST00000505875, ENST00000506850, ENST00000508941, ENST00000509668, ENST00000511031, ENST00000511982, ENST00000514217, ENST00000515665, ENST00000877114

RefSeq mRNA: 2 — MANE Select: NM_002185 NM_001410734, NM_002185

CCDS: CCDS3911

Canonical transcript exons

ENST00000303115 — 8 exons

Exon	Start	End
ENSE00001130269	35873480	35873648
ENSE00001130274	35871056	35871213
ENSE00001130282	35867306	35867463
ENSE00001805007	35875983	35879603
ENSE00002047686	35856891	35857059
ENSE00003475448	35875512	35875587
ENSE00003666759	35874449	35874542
ENSE00003667135	35860852	35860990

Expression profiles

Bgee: expression breadth ubiquitous, 220 present calls, max score 97.85.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 51.0899 / max 3672.3247, expressed in 1029 samples.

FANTOM5 promoters (8 alternative TSS)

Promoter ID	TPM avg	Samples expressed
56110	27.3324	686
56111	19.0782	898
56112	1.9516	204
56109	0.7694	234
56108	0.6947	230
56104	0.6290	151
56113	0.5137	57
56105	0.1210	59

Top tissues by expression

290 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right lung	UBERON:0002167	97.85	gold quality
granulocyte	CL:0000094	97.14	gold quality
lymph node	UBERON:0000029	96.99	gold quality
lower lobe of lung	UBERON:0008949	96.62	gold quality
epithelium of nasopharynx	UBERON:0001951	96.15	gold quality
nasopharynx	UBERON:0001728	96.13	gold quality
vermiform appendix	UBERON:0001154	95.94	gold quality
blood	UBERON:0000178	95.38	gold quality
thymus	UBERON:0002370	95.07	gold quality
upper lobe of left lung	UBERON:0008952	94.78	gold quality
upper lobe of lung	UBERON:0008948	94.73	gold quality
gall bladder	UBERON:0002110	94.10	gold quality
lung	UBERON:0002048	93.39	gold quality
caecum	UBERON:0001153	92.89	gold quality
spleen	UBERON:0002106	92.74	gold quality
visceral pleura	UBERON:0002401	92.74	gold quality
colonic epithelium	UBERON:0000397	92.18	gold quality
small intestine Peyer’s patch	UBERON:0003454	91.93	gold quality
amniotic fluid	UBERON:0000173	91.05	gold quality
small intestine	UBERON:0002108	90.20	gold quality
jejunal mucosa	UBERON:0000399	90.08	gold quality
bone marrow	UBERON:0002371	89.41	gold quality
tonsil	UBERON:0002372	88.92	gold quality
rectum	UBERON:0001052	88.85	gold quality
trabecular bone tissue	UBERON:0002483	88.16	gold quality
superficial temporal artery	UBERON:0001614	87.91	gold quality
bone marrow cell	CL:0002092	87.57	gold quality
ileal mucosa	UBERON:0000331	87.32	gold quality
pleura	UBERON:0000977	87.23	gold quality
parietal pleura	UBERON:0002400	86.59	gold quality

Single-cell (SCXA)

Detected in 48 experiment(s), a significant marker in 37.

Experiment	Marker?	Max mean expression
E-CURD-46	yes	3376.74
E-MTAB-8142	yes	3013.77
E-CURD-120	yes	2795.48
E-MTAB-10553	yes	2745.88
E-CURD-112	yes	2710.99
E-CURD-88	yes	2530.67
E-CURD-122	yes	2472.53
E-GEOD-150728	yes	2351.19
E-HCAD-36	yes	2323.57
E-MTAB-6678	yes	2064.91
E-MTAB-10042	yes	1976.12
E-MTAB-9221	yes	1957.26
E-HCAD-1	yes	1893.19
E-MTAB-10855	yes	1829.62
E-HCAD-15	yes	1803.04

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): AP1, BRD2, BRD4, ETS1, FOS, FOXO1, FOXP1, GABPA, GATA3, GFI1, IKZF1, JUN, MAFB, MYC, NOTCH1, NR3C1, RELA, RUNX1, SPI1, STAT5A, TCF3, ZBTB17

Literature-anchored findings (GeneRIF, showing 40)

• IL-7 may function to regulate the milieu of the microenvironment by modulating IL-6 secretion by the IL-7R-expressing stromal elements (PMID:12149213)
• IL-2 signaling can diminish IL-7Ralpha expression via a phosphatidylinositol 3-kinase/Akt-dependent mechanism. (PMID:12354940)
• IL-7R has a role in some human solid malignancies [review] (PMID:12792903)
• Interaction between IL-7 and its receptor has the major role in modulating T-ALL survival within the microenvironment generated by the T-ALL/TEC interaction. (PMID:14607751)
• Expansion of CD8 positive, CD127 negative effector-like T cells is identified as a novel feature of HIV-associated immune perturbation. (PMID:15728501)
• Maturation of memory CD4 and CD8 T cells is associated with a CD127high phenotype and the expression of CD127 serves as a predictor of the functional quality of antiviral T cells. (PMID:15879083)
• Virus-specific IL-7Ralpha+ cells proliferated vigorously in response to IL-7, IL-15, or peptide, whereas IL-7Ralpha- cells required both peptide and helper-cell activation or IL-2 or IL-15 for optimal expansion (PMID:15947093)
• Altogether, we show that gamma(c) is the target of an ubiquitination mechanism and its expression level can be regulated through the activities of a couple of ubiquitin-ligase/ubiquitin-hydrolase enzymes, namely c-Cbl/DUB-2. (PMID:16004964)
• The T cell proliferation gene IL7R (CD127) was also underexpressed in PPMS, but was up-regulated in SPMS compared to the controls. (PMID:16075257)
• Aging affects IL-7Ralpha expression by T cells, leading to impaired signaling and survival responses to IL-7. (PMID:16357322)
• HIV infection produces the Tat protein, which in turn may up-regulate IL-7R in a paracrine manner, which ultimately promotes early events in HIV replication. (PMID:16614257)
• Transcription of the IL-7R alpha subunit is suppressed in both naive and memory T cells following IL-7 stimulation. (PMID:16709829)
• Cell surface expression of CD127 therefore allows accurate estimation of regulatory T cell numbers and isolation of pure populations for in vitro studies and should contribute to our understanding of regulatory abnormalities in immunopathic diseases. (PMID:16818676)
• CD127 can be used to quantitate regulatory T (Treg) cell subsets in individuals with type 1 diabetes supporting the use of CD127 as a biomarker for human Treg cells. (PMID:16818678)
• CD127 expression on T cells remains low in HIV-infected patients despite antiretroviral therapy (PMID:16837861)
• IL-7 receptor and Notch1 pathways cooperate to synchronize cell proliferation and suppression of non-T lineage choices in primitive intrathymic progenitors. (PMID:16951331)
• CD127 uniquely enables the purification of FOXP3+ Treg cells and, potentially, also “adaptive” regulatory T-cell subsets from the CD4+CD25- T-cell population. (PMID:17045841)
• A large fraction of peripheral HCV-specific CD8+ T cells were CD127+ and KLRG1-. Intrahepatic virus-specific CD8+ T cells displayed significantly reduced levels of CD127 expression but similar levels of KLRG1 expression compared to the peripheral blood. (PMID:17079288)
• CD4+ regulatory T-cells exhibiting suppressive activity in vitro display distinctly lower surface expression of CD127, irrespective of their level of CD25 expression. (PMID:17173927)
• results confirm that signal transduction via the IL-15R, and hence NK ontogeny, is preferentially retained relative to the IL-7R as gammac expression becomes limiting. (PMID:17363735)
• These findings suggest that DNA methylation is involved in regulating IL-7Ralpha expression in T cells via affecting IL-7Ralpha gene promoter activity. (PMID:17442928)
• gene encoding the IL-7Ralpha chain is polymorphic, and investigation of inhalation allergic patients compared with controls showed significant association with two alleles at position +1237 and +2087 (PMID:17504502)
• A subset of naive CD8-positive cells characterized by low interleukin-7 receptor alpha message and protein expression may encompass cells that have recently received homeostatic signals. (PMID:17579041)
• CD4(+)CD25(+)CD45RO(+)IL-7Ralpha(high) cell population contained allospecific CD4 T cells and secreted effector cytokines. (PMID:17591854)
• Increased constitutive interleukin-7 receptor alpha expression has minimal effects on the numbers or function of effector and memory CD8 T cells formed. (PMID:17609371)
• Alleles of IL2RA and IL7RA and those in the HLA locus are identified as heritable risk factors for multiple sclerosis. (PMID:17660530)
• Results provide compelling evidence that polymorphisms in IL7R, which encodes the interleukin 7 receptor alpha chain (IL7Ralpha), indeed contribute to the non-HLA genetic risk in multiple sclerosis. (PMID:17660816)
• Results show allelic association of a polymorphism in interleukin 7 receptor alpha chain (IL7R) as a significant risk factor for multiple sclerosis in four independent family-based or case-control data sets. (PMID:17660817)
• Immunolocalization of IL-7, IL-7Ralpha, SDF-1alpha, and CXCR4 resulted in a diffuse but specific labeling. RT-PCR analysis confirmed the expression of the above-mentioned transcripts. (PMID:17894415)
• Stimulation of the IL-7 pathway begins with IL-7 binding to unglycosylated and glycosylated forms of its alpha-receptor, IL-7 receptor alpha. (PMID:17909291)
• Haplotypes of the IL7R gene are correlated with altered expression in whole blood cells in multiple sclerosis. (PMID:17928869)
• IL-7 reduced CD127-surface expression and shedding by CD8+ T cells; results support a role for IL-7 in the down-regulation of CD127 expression and impairment of CTL function observed in HIV infection (PMID:17956896)
• We report that loss of CD127 defines terminally differentiated B cell-helping effector T cells in human tonsils. (PMID:18025189)
• The association between rs6897932 and multiple sclerosis in the Olmsted County collection appeared to be much stronger than anticipated on the basis of recent studies (PMID:18272905)
• Expression of transgenic IL-7 receptor alpha by itself does not support increased survival of effector antigen-specific CD4 or CD8 T cells into the memory phase following infection with Listeria monocytogenes. (PMID:18292507)
• IL2RA and IL7RA genes confer susceptibility for multiple sclerosis in two independent European populations. (PMID:18354419)
• IL-7- and TCR/CD28-mediated signaling data show that differentially regulate IL-7Ralpha expression on human T cells with a transient and chronic effect, respectively. (PMID:18390701)
• during HIV infection, specific changes in the fraction of CD4(+) T cells expressing CD25 and/or CD127 are associated with disease progression (PMID:18390743)
• Independent replication of the association between the CAPSL and IL7R locus and type 1 diabetes, especially for early-onset type 1 diabetes patients. (PMID:18563381)
• Association studies between IL7RA rs6897932 and multiple sclerosis. (PMID:18721276)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Il7r	ENSMUSG00000003882
rattus_norvegicus	Il7r	ENSRNOG00000065741

Paralogs (7): IL4R (ENSG00000077238), CSF2RB (ENSG00000100368), IL2RB (ENSG00000100385), IL21R (ENSG00000103522), MPL (ENSG00000117400), IL9R (ENSG00000124334), EPOR (ENSG00000187266)

Protein

Protein identifiers

Interleukin-7 receptor subunit alpha — P16871 (reviewed: P16871)

Alternative names: CDw127

All UniProt accessions (6): B8YG18, P16871, D6RCR9, D6RDM4, D6RG28, H0YA41

UniProt curated annotations — full annotation on UniProt →

Function. Receptor for interleukin-7. Also acts as a receptor for thymic stromal lymphopoietin (TSLP).

Subunit / interactions. The IL7 receptor is a heterodimer of IL7R and IL2RG. The TSLP receptor is a heterodimer of CRLF2 and IL7R. Interacts with CD53.

Subcellular location. Cell membrane Cell membrane Secreted.

Post-translational modifications. N-glycosylated IL-7Ralpha binds IL7 300-fold more tightly than the unglycosylated form. Ubiquitinated by MARCHF8; leading to lysosomal degradation.

Disease relevance. Immunodeficiency 104, severe combined (IMD104) [MIM:608971] A form of severe combined immunodeficiency (SCID), a genetically and clinically heterogeneous group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. Patients present in infancy recurrent, persistent infections by opportunistic organisms. The common characteristic of all types of SCID is absence of T-cell-mediated cellular immunity due to a defect in T-cell development. The disease is caused by variants affecting the gene represented in this entry. Multiple sclerosis 3 (MS3) [MIM:612595] A multifactorial, inflammatory, demyelinating disease of the central nervous system. Sclerotic lesions are characterized by perivascular infiltration of monocytes and lymphocytes and appear as indurated areas in pathologic specimens (sclerosis in plaques). The pathological mechanism is regarded as an autoimmune attack of the myelin sheath, mediated by both cellular and humoral immunity. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia and bladder dysfunction. Genetic and environmental factors influence susceptibility to the disease. Disease susceptibility is associated with variants affecting the gene represented in this entry. A polymorphism at position 244 strongly influences susceptibility to multiple sclerosis. Overtransmission of the major ‘C’ allele coding for Thr-244 is detected in offspring affected with multiple sclerosis. In vitro analysis of transcripts from minigenes containing either ‘C’ allele (Thr-244) or ‘T’ allele (Ile-244) shows that the ‘C’ allele results in an approximately two-fold increase in the skipping of exon 6, leading to increased production of a soluble form of IL7R. Thus, the multiple sclerosis associated ‘C’ risk allele of IL7R would probably decrease membrane-bound expression of IL7R. As this risk allele is common in the general population, some additional triggers are probably required for the development and progression of MS.

Domain organisation. The WSXWS motif appears to be necessary for proper protein folding and thereby efficient intracellular transport and cell-surface receptor binding. The box 1 motif is required for JAK interaction and/or activation.

Similarity. Belongs to the type I cytokine receptor family. Type 4 subfamily.

Isoforms (4)

UniProt ID	Names	Canonical?
P16871-1	1, H20	yes
P16871-2	3, H1
P16871-3	4, H6, Secreted
P16871-4	2, Secreted

RefSeq proteins (2): NP_001397663, NP_002176* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR003531	Hempt_rcpt_S_F1_CS	Conserved_site
IPR003961	FN3_dom	Domain
IPR013783	Ig-like_fold	Homologous_superfamily
IPR036116	FN3_sf	Homologous_superfamily
IPR040997	FN3_7	Domain

Pfam: PF00041, PF18447

UniProt features (55 total): strand 17, sequence variant 7, glycosylation site 6, splice variant 4, sequence conflict 4, helix 4, disulfide bond 3, topological domain 2, short sequence motif 2, signal peptide 1, chain 1, transmembrane region 1, turn 1, domain 1, modified residue 1

Structure

Experimental structures (PDB)

8 structures.

PDB	Method	Resolution (Å)
7OPB	X-RAY DIFFRACTION	2.14
3UP1	X-RAY DIFFRACTION	2.15
5J11	X-RAY DIFFRACTION	2.56
3DI2	X-RAY DIFFRACTION	2.7
3DI3	X-RAY DIFFRACTION	2.9
6P50	X-RAY DIFFRACTION	2.9
6P67	X-RAY DIFFRACTION	2.9
9XEA	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P16871-F1	68.52	0.42

Antibody-complex structures (SAbDab): 2 — 6P50, 6P67

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 282

Disulfide bonds (3): 42–57, 74–82, 108–118

Glycosylation sites (6): 65, 151, 182, 232, 233, 49

Function

Pathways and Gene Ontology

Reactome pathways

3 pathways

ID	Pathway
R-HSA-1266695	Interleukin-7 signaling
R-HSA-8856825	Cargo recognition for clathrin-mediated endocytosis
R-HSA-8856828	Clathrin-mediated endocytosis

MSigDB gene sets: 775 (showing top): GOBP_REGULATION_OF_CELL_ACTIVATION, GOBP_REGULATION_OF_DNA_RECOMBINATION, GOBP_NEGATIVE_REGULATION_OF_PEPTIDYL_TYROSINE_PHOSPHORYLATION, WALLACE_PROSTATE_CANCER_RACE_UP, GOBP_NEGATIVE_REGULATION_OF_ADAPTIVE_IMMUNE_RESPONSE, MCLACHLAN_DENTAL_CARIES_UP, GOBP_POSITIVE_REGULATION_OF_HEMOPOIESIS, HOFFMANN_SMALL_PRE_BII_TO_IMMATURE_B_LYMPHOCYTE_DN, RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_UP, MODULE_169, GOBP_REGULATION_OF_PHOSPHORYLATION, REACTOME_CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM, GOBP_RESPONSE_TO_PEPTIDE, GOBP_REGULATION_OF_LEUKOCYTE_APOPTOTIC_PROCESS, GOBP_B_CELL_ACTIVATION

GO Biological Process (26): regulation of DNA recombination (GO:0000018), cell morphogenesis (GO:0000902), B cell homeostasis (GO:0001782), T cell mediated cytotoxicity (GO:0001913), negative regulation of T cell mediated cytotoxicity (GO:0001915), immune response (GO:0006955), signal transduction (GO:0007165), cell surface receptor signaling pathway (GO:0007166), positive regulation of cell population proliferation (GO:0008284), regulation of cell size (GO:0008361), gene expression (GO:0010467), positive regulation of gene expression (GO:0010628), cellular homeostasis (GO:0019725), hemopoiesis (GO:0030097), T cell differentiation in thymus (GO:0033077), positive regulation of T cell differentiation in thymus (GO:0033089), interleukin-7-mediated signaling pathway (GO:0038111), B cell proliferation (GO:0042100), T cell homeostasis (GO:0043029), positive regulation of receptor signaling pathway via JAK-STAT (GO:0046427), lymph node development (GO:0048535), defense response to Gram-positive bacterium (GO:0050830), negative regulation of T cell apoptotic process (GO:0070233), positive regulation of receptor signaling pathway via STAT (GO:1904894), cytokine-mediated signaling pathway (GO:0019221), T cell differentiation (GO:0030217)

GO Molecular Function (4): antigen binding (GO:0003823), cytokine receptor activity (GO:0004896), interleukin-7 receptor activity (GO:0004917), protein binding (GO:0005515)

GO Cellular Component (7): extracellular region (GO:0005576), nucleoplasm (GO:0005654), cytosol (GO:0005829), plasma membrane (GO:0005886), external side of plasma membrane (GO:0009897), clathrin-coated endocytic vesicle membrane (GO:0030669), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-3 pathways:

Category	Pathways
Signaling by Interleukins	1
Clathrin-mediated endocytosis	1
Membrane Trafficking	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	4
lymphocyte homeostasis	2
cytokine-mediated signaling pathway	2
binding	2
DNA recombination	1
regulation of DNA metabolic process	1
anatomical structure morphogenesis	1
leukocyte mediated cytotoxicity	1
T cell mediated immunity	1
negative regulation of leukocyte mediated cytotoxicity	1
T cell mediated cytotoxicity	1
regulation of T cell mediated cytotoxicity	1
negative regulation of T cell mediated immunity	1
immune system process	1
response to stimulus	1
cell communication	1
cellular process	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
signal transduction	1
cell population proliferation	1
regulation of cell population proliferation	1
positive regulation of cellular process	1
regulation of cellular component size	1
macromolecule biosynthetic process	1
gene expression	1
regulation of gene expression	1
positive regulation of macromolecule biosynthetic process	1
homeostatic process	1
cell development	1
T cell differentiation	1
T cell differentiation in thymus	1
regulation of T cell differentiation in thymus	1
positive regulation of T cell differentiation	1
cellular response to interleukin-7	1
B cell activation	1
lymphocyte proliferation	1
cell surface receptor signaling pathway via JAK-STAT	1
regulation of receptor signaling pathway via JAK-STAT	1

Protein interactions and networks

STRING

3203 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
IL7R	IL7	P13232	999
IL7R	IL2RG	P31785	998
IL7R	TSLP	Q969D9	997
IL7R	CRLF2	Q9HC73	997
IL7R	IL2	P01585	942
IL7R	JAK1	P23458	942
IL7R	IL15	P40933	937
IL7R	CD8A	P01732	935
IL7R	CD4	P01730	925
IL7R	JAK3	P52333	919
IL7R	IL2RA	P01589	906
IL7R	STAT5B	P51692	885
IL7R	STAT5A	P42229	877
IL7R	FOXP3	Q9BZS1	871
IL7R	IL4	P05112	870

IntAct

75 interactions, top by confidence:

A	B	Type	Score
IL7	IL7R	psi-mi:“MI:0407”(direct interaction)	0.740
IL7	IL7R	psi-mi:“MI:0915”(physical association)	0.740
IL7R	IL7	psi-mi:“MI:0915”(physical association)	0.740
CAMKV	AP3B1	psi-mi:“MI:0914”(association)	0.640
VAMP5	IL7R	psi-mi:“MI:0915”(physical association)	0.560
TMEM60	IL7R	psi-mi:“MI:0915”(physical association)	0.560
CD302	IL7R	psi-mi:“MI:0915”(physical association)	0.560
FAM3C	IL7R	psi-mi:“MI:0915”(physical association)	0.560
ATP6V0C	IL7R	psi-mi:“MI:0915”(physical association)	0.560
IL7R	TMEM60	psi-mi:“MI:0915”(physical association)	0.560
IL7R	CD302	psi-mi:“MI:0915”(physical association)	0.560
IL7R	FAM3C	psi-mi:“MI:0915”(physical association)	0.560
IL7R	ATP6V0C	psi-mi:“MI:0915”(physical association)	0.560
TMEM120B	IL7R	psi-mi:“MI:0915”(physical association)	0.560
IL7R	MALL	psi-mi:“MI:0915”(physical association)	0.560
IL7R	AGTRAP	psi-mi:“MI:0915”(physical association)	0.560
MS4A1	IL7R	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (134): CISH (Affinity Capture-Western), IL7R (Affinity Capture-Western), CISH (Affinity Capture-Western), SOCS1 (Affinity Capture-Western), SOCS2 (Affinity Capture-Western), PIK3R1 (Affinity Capture-Western), IL7R (Two-hybrid), IL7R (Two-hybrid), IL7R (Two-hybrid), IL7R (Two-hybrid), AGTRAP (Two-hybrid), TMEM120B (Two-hybrid), IL7R (Affinity Capture-Western), IL7R (Proximity Label-MS), FYN (Affinity Capture-Western)

ESM2 similar proteins: A0MSX9, A5HJM1, C8AW46, C8AW47, K9JA28, O02671, O35664, O46561, O70458, P05710, P14787, P15260, P15261, P16297, P16471, P16871, P16872, P16882, P26896, P48356, P48357, P48551, P97378, Q08501, Q13651, Q28172, Q28235, Q38IC7, Q38J85, Q3SYS8, Q4W815, Q5VWK5, Q61727, Q62959, Q63257, Q65Z14, Q6JTA8, Q6PHB0, Q80VH0, Q80XZ4

Diamond homologs: A0MSX9, A5HJM1, P16871, P16872, Q38IC7

SIGNOR signaling

5 interactions.

A	Effect	B	Mechanism
IL7	up-regulates	IL7R	binding
IL7R	up-regulates	JAK1	binding
NOTCH1	“up-regulates quantity by expression”	IL7R	“transcriptional regulation”
NOTCH	“up-regulates quantity by expression”	IL7R	“transcriptional regulation”

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 29 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Diseases of signal transduction by growth factor receptors and second messengers	5	14.9×	5e-03

GO biological processes:

GO term	Partners	Fold	FDR
negative regulation of apoptotic process	6	8.0×	5e-03

Disease & clinical

Cancer significance

From intOGen — cancer-driver classification: activating (oncogene-like) across 4 cancer types — ALL, ESCA, HCC, STAD.

Clinical variants and AI predictions

ClinVar

605 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	46
Likely pathogenic	15
Uncertain significance	212
Likely benign	231
Benign	66

Top pathogenic / likely-pathogenic (30)

Variant ID	HGVS	Classification
1073963	NC_000005.9:g.(?35857060)(35857181_?)del	Pathogenic
1298987	NM_002185.5(IL7R):c.616C>T (p.Arg206Ter)	Pathogenic
1339483	NM_002185.5(IL7R):c.379G>A (p.Val127Ile)	Pathogenic
134528	NM_002185.5(IL7R):c.662G>T (p.Ser221Ile)	Pathogenic
1437489	NM_002185.5(IL7R):c.514del (p.Glu172fs)	Pathogenic
1453790	NM_002185.5(IL7R):c.37del (p.Ser13fs)	Pathogenic
1465004	NM_002185.5(IL7R):c.126C>G (p.Cys42Trp)	Pathogenic
14841	NM_002185.5(IL7R):c.538-1G>A	Pathogenic
14842	NM_002185.5(IL7R):c.651G>A (p.Trp217Ter)	Pathogenic
1706622	NM_002185.5(IL7R):c.470del (p.Lys157fs)	Pathogenic
208851	NM_002185.5(IL7R):c.333T>A (p.Val111=)	Pathogenic
2203628	NM_002185.5(IL7R):c.562del (p.Lys187_Leu188insTer)	Pathogenic
224841	NM_002185.5(IL7R):c.361dup (p.Ile121fs)	Pathogenic
224842	Single allele	Pathogenic
265195	NM_002185.5(IL7R):c.221+2T>G	Pathogenic
2697973	NM_002185.5(IL7R):c.639_640insTTTTTTTTTTTTTTTTTTTTNNNNNNNNNNTGATCCGCCCGCCTCGGCCTCCCAAAGTGCTGGGATTACAGGCGTGAGCCACCGCGCCCGGCCCCCTGATCACTATTTT (p.Lys214delinsPhePhePhePhePhePheXaaXaaXaaXaaTer)	Pathogenic
2708090	NM_002185.5(IL7R):c.190_193dup (p.Asn65fs)	Pathogenic
2734712	NM_002185.5(IL7R):c.76C>T (p.Gln26Ter)	Pathogenic
2734713	NM_002185.5(IL7R):c.177del (p.Phe59fs)	Pathogenic
2734714	NM_002185.5(IL7R):c.493del (p.His165fs)	Pathogenic
2734715	NM_002185.5(IL7R):c.589_598del (p.Pro197fs)	Pathogenic
2763597	NM_002185.5(IL7R):c.80del (p.Asn27fs)	Pathogenic
2780052	NM_002185.5(IL7R):c.623del (p.Ile208fs)	Pathogenic
2789689	NM_002185.5(IL7R):c.538-2A>G	Pathogenic
2982246	NM_002185.5(IL7R):c.752del (p.Phe251fs)	Pathogenic
3068274	NM_002185.5(IL7R):c.860del (p.Cys287fs)	Pathogenic
3246329	NC_000005.9:g.(?35860934)(35861112_?)del	Pathogenic
3246330	NC_000005.9:g.(?35873562)(35876588_?)del	Pathogenic
353259	NM_002185.5(IL7R):c.83-2A>T	Pathogenic
36392	NM_002185.5(IL7R):c.353G>A (p.Cys118Tyr)	Pathogenic

SpliceAI

1270 predictions. Top by Δscore:

Variant	Effect	Δscore
5:35860850:A:AG	acceptor_gain	1.0000
5:35860851:G:GG	acceptor_gain	1.0000
5:35860851:GGA:G	acceptor_gain	1.0000
5:35860977:G:GT	donor_gain	1.0000
5:35867304:A:AG	acceptor_gain	1.0000
5:35867304:AGT:A	acceptor_gain	1.0000
5:35867304:AGTG:A	acceptor_gain	1.0000
5:35867304:AGTGG:A	acceptor_gain	1.0000
5:35867305:G:GG	acceptor_gain	1.0000
5:35867305:GTG:G	acceptor_gain	1.0000
5:35867305:GTGG:G	acceptor_gain	1.0000
5:35867305:GTGGG:G	acceptor_gain	1.0000
5:35871051:TCCA:T	acceptor_loss	1.0000
5:35871052:CCAG:C	acceptor_loss	1.0000
5:35871054:A:AG	acceptor_gain	1.0000
5:35871054:A:T	acceptor_loss	1.0000
5:35871055:G:GA	acceptor_gain	1.0000
5:35871055:GT:G	acceptor_gain	1.0000
5:35871055:GTT:G	acceptor_gain	1.0000
5:35871055:GTTA:G	acceptor_gain	1.0000
5:35871055:GTTAA:G	acceptor_gain	1.0000
5:35871147:G:GT	donor_gain	1.0000
5:35871147:GAA:G	donor_gain	1.0000
5:35871150:G:GG	donor_gain	1.0000
5:35875583:GAAAA:G	donor_gain	1.0000
5:35875588:G:GG	donor_gain	1.0000
5:35876163:G:GT	donor_gain	1.0000
5:35860849:CA:C	acceptor_loss	0.9900
5:35860850:A:C	acceptor_loss	0.9900
5:35860850:AG:A	acceptor_gain	0.9900

AlphaMissense

3037 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
5:35873559:G:C	R206P	0.999
5:35873600:T:A	W220R	0.998
5:35873600:T:C	W220R	0.998
5:35873602:G:C	W220C	0.998
5:35873602:G:T	W220C	0.998
5:35873561:T:C	S207P	0.997
5:35873603:A:C	S221R	0.997
5:35873605:T:A	S221R	0.997
5:35873605:T:G	S221R	0.997
5:35873594:A:C	S218R	0.995
5:35873596:T:A	S218R	0.995
5:35873596:T:G	S218R	0.995
5:35860899:A:C	S44R	0.993
5:35860901:C:A	S44R	0.993
5:35860901:C:G	S44R	0.993
5:35871056:T:A	V127D	0.993
5:35871124:T:C	F150L	0.993
5:35871126:T:A	F150L	0.993
5:35871126:T:G	F150L	0.993
5:35873585:G:C	G215R	0.993
5:35860933:T:C	L55P	0.992
5:35860938:T:C	C57R	0.992
5:35873556:T:A	V205D	0.992
5:35860893:T:C	C42R	0.991
5:35873595:G:T	S218I	0.991
5:35871071:C:A	P132H	0.990
5:35871181:T:G	Y169D	0.990
5:35860938:T:A	C57S	0.989
5:35860939:G:C	C57S	0.989
5:35871178:G:C	A168P	0.989

dbSNP variants (sampled 300 via entrez): RS1000047499 (5:35866630 T>A), RS1000140927 (5:35878629 A>C), RS1000195413 (5:35860207 G>A), RS1000207637 (5:35874490 T>A,G), RS1000269004 (5:35878833 TGAA>T), RS1000417037 (5:35866437 C>A,G), RS1000471252 (5:35863284 G>C), RS1000812835 (5:35873335 G>A), RS1000888959 (5:35870679 T>C), RS1001067467 (5:35875819 G>A), RS1001075840 (5:35861666 G>A), RS1001167284 (5:35876899 C>T), RS1001175902 (5:35855853 A>C,G,T), RS1001191563 (5:35862966 C>T), RS1001215074 (5:35877051 G>T)

Disease associations

OMIM: gene MIM:146661 | disease phenotypes: MIM:608971, MIM:612595, MIM:254500, MIM:603554

GenCC curated gene-disease

Disease	Classification	Inheritance
immunodeficiency 104	Definitive	Autosomal recessive
T-B+ severe combined immunodeficiency due to IL-7Ralpha deficiency	Supportive	Autosomal recessive
Omenn syndrome	Supportive	Autosomal recessive

ClinGen Gene-Disease Validity (1)

Expert-panel classifications — Definitive > Strong > Moderate > Limited > Disputed > Refuted.

Disease	Classification	Inheritance
immunodeficiency 104	Definitive	AR

Mondo (7): immunodeficiency 104 (MONDO:0012163), T-B+ severe combined immunodeficiency due to IL-7Ralpha deficiency (MONDO:0015701), severe combined immunodeficiency (MONDO:0015974), breast neoplasm (MONDO:0021100), multiple sclerosis, susceptibility to, 3 (MONDO:0012957), plasma cell myeloma (MONDO:0009693), Omenn syndrome (MONDO:0011338)

Orphanet (5): T-B+ severe combined immunodeficiency due to IL-7Ralpha deficiency (Orphanet:169154), Severe combined immunodeficiency (Orphanet:183660), Multiple myeloma (Orphanet:29073), AL amyloidosis (Orphanet:85443), Omenn syndrome (Orphanet:39041)

HPO phenotypes

59 total (30 of 59 shown, HPO-id order):

HPO	Term
HP:0000007	Autosomal recessive inheritance
HP:0000100	Nephrotic syndrome
HP:0000155	Oral ulcer
HP:0000388	Otitis media
HP:0000403	Recurrent otitis media
HP:0000821	Hypothyroidism
HP:0000944	Abnormal metaphysis morphology
HP:0000958	Dry skin
HP:0000964	Eczematoid dermatitis
HP:0000969	Edema
HP:0000989	Pruritus
HP:0001019	Erythroderma
HP:0001072	Thickened skin
HP:0001433	Hepatosplenomegaly
HP:0001508	Failure to thrive
HP:0001596	Alopecia
HP:0001744	Splenomegaly
HP:0001831	Short toe
HP:0001875	Decreased total neutrophil count
HP:0001880	Increased total eosinophil count
HP:0001888	Decreased total lymphocyte count
HP:0001903	Anemia
HP:0001945	Fever
HP:0001973	Autoimmune thrombocytopenia
HP:0001974	Increased total leukocyte count
HP:0002014	Diarrhea
HP:0002020	Gastroesophageal reflux
HP:0002028	Chronic diarrhea
HP:0002090	Pneumonia
HP:0002240	Hepatomegaly

GWAS associations

43 associations (top):

Study	Trait	p-value
GCST000038_8	Type 1 diabetes	8.000000e-06
GCST000062_6	Multiple sclerosis	3.000000e-07
GCST000424_9	Multiple sclerosis	2.000000e-06
GCST000949_1	Multiple sclerosis	4.000000e-07
GCST000964_43	Ulcerative colitis	4.000000e-08
GCST001010_2	Primary biliary cholangitis	1.000000e-11
GCST001198_25	Multiple sclerosis	2.000000e-08
GCST001685_1	Primary biliary cholangitis	4.000000e-08
GCST003129_22	Primary biliary cholangitis	5.000000e-11
GCST003184_13	Atopic dermatitis	2.000000e-10
GCST003184_5	Atopic dermatitis	3.000000e-14
GCST004145_4	Primary biliary cholangitis	6.000000e-09
GCST004627_62	Lymphocyte count	2.000000e-43
GCST004632_111	Lymphocyte percentage of white cells	3.000000e-29
GCST004633_53	Neutrophil percentage of white cells	2.000000e-19
GCST005038_42	Allergic disease (asthma, hay fever or eczema)	9.000000e-36
GCST005529_10	Ankylosing spondylitis	5.000000e-07
GCST005529_67	Ankylosing spondylitis	2.000000e-06
GCST005531_115	Multiple sclerosis	4.000000e-17
GCST005536_13	Type 1 diabetes	4.000000e-08
GCST005581_3	Primary biliary cirrhosis	2.000000e-13
GCST006409_29	Allergic rhinitis	4.000000e-32
GCST006585_1306	Blood protein levels	1.000000e-18
GCST007036_3	Primary biliary cholangitis	2.000000e-09
GCST007563_11	Allergic disease (asthma, hay fever or eczema)	3.000000e-15
GCST007564_36	Asthma or allergic disease (pleiotropy)	2.000000e-14
GCST007798_69	Asthma	2.000000e-13
GCST007799_44	Asthma (adult onset)	9.000000e-14
GCST007941_39	Medication use (adrenergics, inhalants)	9.000000e-10
GCST008916_32	Asthma	1.000000e-10

EFO canonical traits (8, from GWAS)

EFO ID	Trait name
EFO:0004267	biliary liver cirrhosis
EFO:0004587	lymphocyte count
EFO:0007993	lymphocyte percentage of leukocytes
EFO:0007990	neutrophil percentage of leukocytes
EFO:1002011	adult onset asthma
EFO:0009941	Inhalant adrenergic use measurement
EFO:0007992	basophil percentage of leukocytes
EFO:0007989	monocyte percentage of leukocytes

MeSH disease descriptors (4)

Descriptor	Name	Tree numbers
D001943	Breast Neoplasms	C04.588.180; C17.800.090.500
D009101	Multiple Myeloma	C04.557.595.500; C14.907.454.460; C15.378.147.780.650; C15.378.463.515.460; C20.683.515.845; C20.683.780.650
D016511	Severe Combined Immunodeficiency	C16.320.798.750; C16.614.815; C18.452.284.800; C20.673.795.750
C563822	Severe Combined Immunodeficiency, Autosomal Recessive, T Cell Negative, B Cell Positive, NK Cell Positive (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB variants

1 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs6897932	IL7R		0.00	0

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: catalytic receptor — IL-2 receptor family

Most potent curated ligand interactions (2 total), top 2:

Ligand	Action	Affinity	Parameter
lusvertikimab	Antagonist	11.4	pEC50
bempikibart	Binding	9.0	pEC50

CTD chemical–gene interactions

88 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
(+)-JQ1 compound	decreases reaction, decreases expression, increases expression, affects binding	8
sodium arsenite	decreases expression, affects cotreatment, increases abundance, increases expression, affects methylation	6
bisphenol A	decreases expression, decreases methylation, increases expression	3
Estradiol	affects expression, affects cotreatment, increases expression	3
potassium chromate(VI)	decreases expression, increases expression, affects cotreatment	2
nickel sulfate	increases expression	2
Bortezomib	increases expression, increases response to substance	2
Arsenic	increases abundance, increases expression, affects expression, affects cotreatment	2
Benzo(a)pyrene	decreases expression, increases expression	2
Calcitriol	decreases expression	2
Copper	increases expression, affects binding, decreases expression	2
Nickel	increases expression	2
Dronabinol	increases expression, decreases reaction	2
Cadmium Chloride	increases expression	2
Nanotubes, Carbon	increases expression	2
Glupearl 19S	increases expression	1
triphenyl phosphate	affects expression	1
propionaldehyde	increases expression	1
captax	increases expression	1
geraniol	increases expression	1
lead acetate	decreases expression	1
trichostatin A	increases expression	1
cinnamaldehyde	increases expression	1
arsenite	affects binding, decreases reaction	1
afimoxifene	increases expression	1
butyraldehyde	increases expression	1
perfluorooctanoic acid	decreases expression	1
manganese chloride	increases abundance, increases expression, affects cotreatment	1
cobalt sulfate	increases expression	1
4-hydroxy-2-nonenal	decreases expression	1

Cellosaurus cell lines

6 cell lines: 4 cancer cell line, 2 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B8II	Abcam HCT 116 IL7R KO	Cancer cell line	Male
CVCL_B8XG	Abcam MCF-7 IL7R KO	Cancer cell line	Female
CVCL_B9KS	Abcam A-549 IL7R KO	Cancer cell line	Male
CVCL_D9H7	Ubigene HEK293 IL7R KO	Transformed cell line	Female
CVCL_E0F7	Ubigene HeLa IL7R KO	Cancer cell line	Female
CVCL_E8EI	HEK-Blue IL-7	Transformed cell line	Female

Clinical trials (associated diseases)

301 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00092183	PHASE4	COMPLETED	An Investigational Drug for the Prevention of Chemotherapy-Induced Nausea and Vomiting (MK-0869-071)
NCT00128778	PHASE4	COMPLETED	Maintenance Treatment With Liposomal Doxorubicin (Caelyx) in Metastatic Breast Cancer Patients
NCT00302120	PHASE4	UNKNOWN	The MONET - Study: MR Mammography of Nonpalpable Breast Tumors
NCT00307606	PHASE4	UNKNOWN	Does a Single Steroid Injection Reduce the Formation of Postmastectomy Seroma
NCT00370240	PHASE4	COMPLETED	Chlorhydrate of Ropivacaine and Breast Cancer Surgery
NCT00375752	PHASE4	TERMINATED	Efficacy and Safety of Letrozole vs. Letrozole Plus Zoledronic Acid as Endocrine Therapy Before Surgery in Postmenopausal Patients With Breast Cancer
NCT00575354	PHASE4	COMPLETED	Comparison of Sevoflurane and Isoflurane Anesthesia for Benign Breast Tumor Excision
NCT00604968	PHASE4	TERMINATED	Pegylated Liposomal Doxorubicin (Caelyx(R)) as Monotherapy in Elderly Patients With Locally Advanced and/or Metastatic Breast Cancer (Study P05059)
NCT00616135	PHASE4	COMPLETED	Study of Autologous Fat Enhanced w/ Regenerative Cells Transplanted to Reconstruct Breast Deformities After Lumpectomy
NCT00649090	PHASE4	COMPLETED	A Study to Evaluate the Safety of Adjuvant Treatment With Exemestane Following Previous Treatment With Tamoxifen in Postmenopausal Women With Estrogen Sensitive Primary Breast Cancer
NCT00779285	PHASE4	TERMINATED	Safety Study of CAELYX in Patients With Metastatic Breast Cancer Previously Treated With Anthracyclines (Study P04057)(TERMINATED)
NCT01176916	PHASE4	COMPLETED	Aromasin® Interventional Study Of Early Invasive Breast Cancer Patients In China
NCT01427400	PHASE4	UNKNOWN	The Use of Botulinum Toxin A in Two-Stage Tissue Expander/ Implant Breast Reconstruction
NCT01849380	PHASE4	UNKNOWN	Neoadjuvant ECS Versus ECF in Local Advanced Breast Cancer
NCT01859936	PHASE4	COMPLETED	Will Preoperative MRI Breast in Women Under 56 Years With Breast Cancer Change Primary Treatment
NCT01948960	PHASE4	COMPLETED	Influence of Exceptional Patient Characteristics on Everolimus Exposure
NCT01961544	PHASE4	COMPLETED	Eribulin Mesylate Phase IV Clinical Trial in Korean Patients With Metastatic or Locally Advanced Breast Cancer
NCT01975064	PHASE4	COMPLETED	Cancer and Anesthesia: Survival After Radical Surgery - a Comparison Between Propofol or Sevoflurane Anesthesia
NCT02004834	PHASE4	ACTIVE_NOT_RECRUITING	Levobupivacaine and Lidocaine for Paravertebral Block Causes Greater Hemodynamic Oscillations Than Levobupivacaine
NCT02372305	PHASE4	WITHDRAWN	Comparison of FlexHD and Alloderm Outcomes in Breast Reconstructive Surgery
NCT02479347	PHASE4	COMPLETED	Wound Infections in Breast Cancer Surgery After Preoperative Skin Preparation With Chlorhexidine vs. Povidone-iodine
NCT02549677	PHASE4	COMPLETED	Epirubicin Versus Docetaxel Plus Cyclophosphamide in Lymph Node Negative, ER-positive, Her2-negative Breast Cancer
NCT02612870	PHASE4	UNKNOWN	Sienna+® Injection Time Study 4 Arms
NCT02627560	PHASE4	COMPLETED	The Effect of Topical Tranexamic Acid on Bleeding and Seroma Formation in After Undergoing Mastectomy
NCT02661932	PHASE4	COMPLETED	Fertility Preservation in Breast Cancer Patients
NCT02781259	PHASE4	UNKNOWN	Selective Lymph Node Dissection Using Fluorescent Dye in Node-positive Breast Cancer
NCT02819921	PHASE4	TERMINATED	Desvenlafaxine for Treatment of Hot Flashes in Women With Breast Cancer Taking Tamoxifen
NCT03220178	PHASE4	TERMINATED	Impact of eHealth-support on Quality of Life in Metastatic Breast Cancer Patients Treated With Palbociclib and Endocrine Therapy
NCT03583944	PHASE4	COMPLETED	A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer
NCT03586154	PHASE4	COMPLETED	Combined Intra-articular Shoulder Injection and Stellate Ganglion Block in Chronic Post-mastectomy Shoulder Pain
NCT04707196	PHASE4	COMPLETED	A Study of Abemaciclib in Indian Women With Advanced Breast Cancer
NCT04931615	PHASE4	COMPLETED	ARTISS a Single-centre Randomised Control Study
NCT05033769	PHASE4	UNKNOWN	Assessing ImmunoResponse Post Eribulin: Eribulin and Immunogenicity in Advanced Breast Cancer
NCT05036005	PHASE4	UNKNOWN	Neoadjuvant Ontruzant (SB3) in Patients With HER2-positive Early Breast Cancer: An Open-Label (NeoON)
NCT05452213	PHASE4	RECRUITING	Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients
NCT05465031	PHASE4	RECRUITING	Sacubitril/Valsartan in PriMAry preventIoN of the Cardiotoxicity of Systematic breaST canceR trEAtMent (MAINSTREAM)
NCT05949333	PHASE4	UNKNOWN	Reducing Neutropenia Incidence With Pegfilgrastim Administration on Day 3 After Chemotherapy
NCT07158164	PHASE4	RECRUITING	DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment
NCT07162259	PHASE4	NOT_YET_RECRUITING	Cohort Study on Sequential ADC Therapy in HR-positive/HER2-negative Advanced Breast Cancer
NCT00220766	PHASE3	COMPLETED	Rapid Infusion of Immune Globulin Intravenous (Human) In Primary Immunodeficiency Patients